全文获取类型
收费全文 | 4030篇 |
免费 | 327篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 147篇 |
妇产科学 | 61篇 |
基础医学 | 730篇 |
口腔科学 | 32篇 |
临床医学 | 452篇 |
内科学 | 851篇 |
皮肤病学 | 68篇 |
神经病学 | 476篇 |
特种医学 | 74篇 |
外科学 | 442篇 |
综合类 | 14篇 |
一般理论 | 2篇 |
预防医学 | 369篇 |
眼科学 | 48篇 |
药学 | 279篇 |
中国医学 | 9篇 |
肿瘤学 | 292篇 |
出版年
2024年 | 2篇 |
2023年 | 40篇 |
2022年 | 55篇 |
2021年 | 101篇 |
2020年 | 62篇 |
2019年 | 102篇 |
2018年 | 112篇 |
2017年 | 73篇 |
2016年 | 81篇 |
2015年 | 105篇 |
2014年 | 156篇 |
2013年 | 203篇 |
2012年 | 313篇 |
2011年 | 342篇 |
2010年 | 171篇 |
2009年 | 170篇 |
2008年 | 290篇 |
2007年 | 284篇 |
2006年 | 283篇 |
2005年 | 278篇 |
2004年 | 259篇 |
2003年 | 279篇 |
2002年 | 220篇 |
2001年 | 29篇 |
2000年 | 22篇 |
1999年 | 33篇 |
1998年 | 41篇 |
1997年 | 51篇 |
1996年 | 31篇 |
1995年 | 23篇 |
1994年 | 31篇 |
1993年 | 33篇 |
1992年 | 7篇 |
1991年 | 14篇 |
1990年 | 10篇 |
1989年 | 8篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 12篇 |
1985年 | 2篇 |
1984年 | 11篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1980年 | 5篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1965年 | 1篇 |
1964年 | 1篇 |
1962年 | 1篇 |
排序方式: 共有4381条查询结果,搜索用时 15 毫秒
91.
Morgan Vandermeulen Céline Grégoire Alexandra Briquet Chantal Lechanteur Yves Beguin Olivier Detry 《World journal of gastroenterology : WJG》2014,20(44):16418-16432
Mesenchymal stromal cells(MSCs) are multipotent and self-renewing cells that reside essentially in the bone marrow as a non-hematopoietic cell population, but may also be isolated from the connective tissues of most organs. MSCs represent a heterogeneous population of adult, fibroblast-like cells characterized by their ability to differentiate into tissues of mesodermal lineages including adipocytes, chondrocytes and osteocytes. For several years now, MSCs have been evaluated for their in vivo and in vitro immunomodulatory and ‘tissue reconstruction’ properties, which could make them interesting in various clinical settings, and particularly in organ transplantation. This paper aims to review current knowledge on the properties of MSCs and their use in pre-clinical and clinical studies in solid organ transplantation, and particularly in the field of liver transplantation. The first available clinical data seem to show that MSCs are safe to use, at least in the medium-term, but more time is needed to evaluate the potential adverse effects of long-term use. Many issues must be resolved on the correct use of MSCs. Intensive in vitro and pre-clinical research are the keys to a better understanding of the way that MSCs act, and to eventually lead to clinical success. 相似文献
92.
Salwa Sebti Christine Prébois Esther Pérez-Gracia Chantal Bauvy Fabienne Desmots Nelly Pirot Céline Gongora Anne-Sophie Bach Andrew V. Hubberstey Valérie Palissot Guy Berchem Patrice Codogno Laetitia K. Linares Emmanuelle Liaudet-Coopman Sophie Pattingre 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(11):4115-4120
93.
Hélène Hanaire MD Sylvia Franc MD Sophie Borot PhD Alfred Penfornis PhD Pierre-Yves Benhamou PhD Pauline Schaepelynck MD Eric Renard PhD Bruno Guerci PhD Nathalie Jeandidier PhD Chantal Simon PhD Patrick Hannaert PhD Ilham Xhaard PhD Maeva Doron PhD Erik Huneker PhD Guillaume Charpentier MD Yves Reznik PhD 《Diabetes, obesity & metabolism》2020,22(3):324-334
94.
Agostino Consoli MD Leszek Czupryniak MD Rui Duarte MD György Jermendy MD Alexandra Kautzky-Willer MD Chantal Mathieu MD Miguel Melo MD Ofri Mosenzon MD Frank Nobels MD Nikolaos Papanas MD Gabriela Roman MD Oliver Schnell MD Alexis Sotiropoulos MD Coen D. A. Stehouwer MD Cees J. Tack MD Vincent Woo MD Gian Paolo Fadini MD Itamar Raz MD 《Diabetes, obesity & metabolism》2020,22(10):1705-1713
The large number of pharmacological agents available to treat type 2 diabetes (T2D) makes choosing the optimal drug for any given patient a complex task. Because newer agents offer several advantages, whether and when sulphonylureas (SUs) should still be used to treat T2D is controversial. Published treatment guidelines and recommendations should govern the general approach to diabetes management. However, expert opinions can aid in better understanding local practices and in formulating individual choices. The current consensus paper aims to provide additional guidance on the use of SUs in T2D. We summarize current local treatment guidelines in European countries, showing that SUs are still widely proposed as second-line treatment after metformin and are often ranked at the same level as newer glucose-lowering medications. Strong evidence now shows that sodium-glucose co-transporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with low hypoglycaemia risk, promote weight loss, and exert a positive impact on vascular, cardiac and renal endpoints. Thus, using SUs in place of SGLT-2is and GLP-1RAs may deprive patients of key advantages and potentially important cardiorenal benefits. In subjects with ascertained cardiovascular disease or at very high cardiovascular risk, SGLT-2is and/or GLP-1RAs should be used as part of diabetes management, in the absence of contraindications. Routine utilization of SUs as second-line agents continues to be acceptable in resource-constrained settings. 相似文献
95.
96.
97.
98.
99.
100.